ArticleFungal biology and biotechnology2025
A CRISPR Cas12a/Cpf1 strategy to facilitate robust multiplex gene editing in Aspergillus Niger.
Article in Fungal biology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CRISPR/Cas systems in fungal biotechnology: advancing high-value metabolite synthesis for industrial and food security applications.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCRISPR technologies have revolutionized strain engineering of Aspergillus species, and drastically increased the ease and speed at which genomic modifications can be performed. One of the advantages of CRISPR technologies is the possibility of rapid strain engineering using multiplex experiments. This can be achieved by using a set of different guiding RNA molecules (gRNA) to target multiple loci in the same experiment. Two major challenges in such experiments are firstly, the delivery of multiple guides simultaneously, and secondly, ensuring that each target locus is cut efficiently by the CRISPR nuclease. The CRISPR nuclease Cas12a, also known as Cpf1, presents a unique advantage to bypass this challenge. Specifically, and unlike Cas9, Cpf1 is able to release several gRNAs from a common precursor RNA molecule through its own RNase activity, eliminating the need for elements such as ribozymes or tRNA machinery for gRNA maturation. This feature sets the stage for much more straightforward construction of vectors for the delivery of many gRNAs, which in turn allows each locus to be targeted by multiple gRNAs to increase the odds of successfully inducing a break in the DNA.
resultsHere we present a toolbox that can be used to assemble plasmids containing a gRNA multiplex expression cassette, which is able to express a multi gRNA precursor. The precursor can be processed via Cpf1 RNase activity to produce multiple functional gRNAs in vivo. Using our setup, we have constructed plasmids that are able to deliver up to ten gRNAs. In addition, we show that three simultaneous deletions can be introduced robustly in Aspergillus niger by targeting each gene with several gRNAs, without prior gRNA validation or the use of genomically integrated selection markers.
conclusionIn this study we have established an efficient system for the construction of CRISPR-Cpf1 vectors that are able to deliver a large number of gRNAs for multiplex genome editing in Aspergillus species. Our strategy allows multiple specific genomic modifications to be performed in a time frame of less than two weeks, and we envision this will be able to speed up cell factory construction efforts significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.